Achieving Aseptic Drying With Spray Drying Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Achieving Aseptic Drying With Spray Drying Technologies
Henrik Schwartzbach, senior process technologist at GEA Niro, explins why spray drying is seeing increased uptake in the pharma industry.


Pharmaceutical Technology Europe
Volume 23, Issue 9

How does aseptic spray drying compare with other aseptic technologies?

Liquid formulations are the preferred drug delivery solution for a wide range of sterile pharmaceuticals because they are well accepted with low-cost processes and offer relatively good convenience for the user. Product stability and cold chain challenges, however, make dry formulations attractive solutions as well.

Today, most dry formulations are produced by lyophilisation, which is a long-established process for producing stable powders, but has a high-total cost for installation and operation. It is also a lengthy batch process (often up to 48 h to process a batch) that carries the risk of losing a whole batch if, for any reason, process conditions are not maintained throughout the cycle. To reduce the risk of losing a batch, there should be backup systems in place, but this increases both installation and operation costs.

Compared with lyophilisation, spray drying is generally more flexible in terms of product and powder characteristics and processing time. However, the yields in spray drying processes are typically around 98–99% rather than 100%, which is the theoretical level that can be obtained in a lyophiliser (under the condition that all batches are successfully processed and that all vials come out in perfect shape). This can make a significant difference on expensive products. Additionally, because spray drying is very flexible in terms of product and powder characteristics, there are possibilities for making the wrong powder characteristics. In many cases, this is apparent only as poor yield. For small development batches produced on small laboratory or pilot spray dryers (frequently with non-optimised process conditions and equipment), the yield may be significantly less than what can be achieved on full batches and with optimised process conditions. This is important to keep in mind in order to avoid rejecting the spray drying technology due to wrong selection of process conditions or equipment.

Comparing the costs of the two technologies, spray drying is in general more economical in terms of installation and operation compared with lyophilisation. For instance, the evaporative capacity of a normal-sized pharmaceutical spray dryer can match that of 5–7 large lyophilisers. Full operational and life cycle costs must also be considered when comparing the two technologies.

In many cases, however, spray drying and lyophilisation are complementary technologies. For small batches of difficult-to-dry powders to be supplied in vials, lyophilisation has an advantage, whereas spray drying has an advantage if free-flowing powders are required, and for productions in large quantities.

Henrik Schwartzbach Senior Process Technologist at GEA Niro


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here